StocksFundsScreenerSectorsWatchlists
LH

LH - Laboratory Corp of America Holdings Stock Price, Fair Value and News

205.72USD-0.78 (-0.38%)Market Closed

Market Summary

LH
USD205.72-0.78
Market Closed
-0.38%

LH Alerts

  • 3 major insider sales recently.

LH Stock Price

View Fullscreen

LH RSI Chart

LH Valuation

Market Cap

17.3B

Price/Earnings (Trailing)

41.39

Price/Sales (Trailing)

1.42

Price/Free Cashflow

19.79

LH Price/Sales (Trailing)

LH Profitability

Operating Margin

25.14%

Return on Equity

5.31%

Return on Assets

2.5%

Free Cashflow Yield

5.05%

LH Fundamentals

LH Revenue

Revenue (TTM)

12.2B

Rev. Growth (Yr)

-27.47%

Rev. Growth (Qtr)

-0.77%

LH Earnings

Earnings (TTM)

418.0M

Earnings Growth (Yr)

-319.58%

Earnings Growth (Qtr)

-191.16%

Breaking Down LH Revenue

Last 7 days

-2.6%

Last 30 days

-4.6%

Last 90 days

-7.9%

Trailing 12 Months

3.3%

How does LH drawdown profile look like?

LH Financial Health

Current Ratio

1.17

Debt/Equity

0.51

Debt/Cashflow

0.33

LH Investor Care

Buy Backs (1Y)

18.36%

Diluted EPS (TTM)

4.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202311.0B11.4B11.8B12.2B
20229.6B8.7B7.5B10.6B
202118.1B19.2B22.3B13.1B
202010.9B10.2B9.5B16.8B
201911.4B11.4B11.5B11.6B
201810.7B11.1B11.3B11.3B
20179.6B9.7B9.9B10.3B
201616.5B16.7B16.8B16.8B
20156.4B7.1B7.9B8.7B
201410.4B10.4B10.5B10.6B
20135.7B5.7B5.8B5.8B
20125.6B5.6B5.6B5.7B
20115.2B5.3B5.5B5.5B
20104.7B4.8B4.9B5.0B
20094.6B4.6B4.6B4.7B
200804.2B4.4B4.5B
20070004.1B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Laboratory Corp of America Holdings

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
summy amy b.
sold
-760,515
217
-3,500
evp, chief marketing officer
Apr 01, 2024
bailey megan d.
acquired
-
-
205
evp, chief strategy officer
Apr 01, 2024
schroeder mark s
sold
-1,407,390
217
-6,477
evp, pres diagnostics & coo
Apr 01, 2024
bailey megan d.
sold (taxes)
-14,928
216
-69.00
evp, chief strategy officer
Mar 28, 2024
van der vaart sandra d
sold
-770,077
216
-3,553
evp, chief legal officer
Mar 27, 2024
wilkinson peter j
acquired
-
-
3,079
svp, chief accounting officer
Mar 27, 2024
wilkinson peter j
sold (taxes)
-193,614
216
-894
svp, chief accounting officer
Mar 27, 2024
eisenberg glenn a
acquired
-
-
20,033
chief financial officer, evp
Mar 27, 2024
berberian lance
sold (taxes)
-714,464
216
-3,299
evp, cio & cto
Mar 27, 2024
van der vaart sandra d
sold (taxes)
-564,165
216
-2,605
evp, chief legal officer

1–10 of 50

Which funds bought or sold LH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
Fortitude Family Office, LLC
unchanged
-
-336
8,301
0.01%
Apr 11, 2024
City State Bank
unchanged
-
-
2,000
-%
Apr 11, 2024
SALEM INVESTMENT COUNSELORS INC
unchanged
-
-81,616
2,019,230
0.07%
Apr 11, 2024
Cooper Financial Group
added
6.73
24,469
976,917
0.16%
Apr 11, 2024
Crestmont Private Wealth LLC
added
37.03
107,817
447,843
0.22%
Apr 11, 2024
OPTIMUM INVESTMENT ADVISORS
unchanged
-
-20,751
513,381
0.24%
Apr 11, 2024
Gulf International Bank (UK) Ltd
unchanged
-
-65,000
1,589,000
0.04%
Apr 10, 2024
Fragasso Group Inc.
reduced
-1.71
-262,587
4,485,170
0.38%
Apr 10, 2024
Czech National Bank
added
0.46
-116,447
3,263,360
0.04%
Apr 10, 2024
SOA Wealth Advisors, LLC.
unchanged
-
-17.00
443
-%

1–10 of 50

Are Funds Buying or Selling LH?

Are funds buying LH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LH
No. of Funds

Unveiling Laboratory Corp of America Holdings's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.48%
9,745,265
SC 13G/A
Jan 30, 2024
blackrock inc.
12.4%
10,488,875
SC 13G/A
Feb 10, 2023
blackrock inc.
13.0%
11,474,507
SC 13G/A
Feb 09, 2023
vanguard group inc
11.79%
10,450,115
SC 13G/A
Jan 26, 2023
blackrock inc.
13.0%
11,474,507
SC 13G/A
Jan 20, 2023
blackrock inc.
13.0%
11,474,507
SC 13G/A
Mar 09, 2022
blackrock inc.
10.4%
9,706,541
SC 13G/A
Feb 10, 2022
vanguard group inc
11.24%
10,753,065
SC 13G/A
Feb 01, 2022
blackrock inc.
8.6%
8,274,411
SC 13G/A
Feb 10, 2021
vanguard group inc
10.68%
10,405,602
SC 13G/A

Recent SEC filings of Laboratory Corp of America Holdings

View All Filings
Date Filed Form Type Document
Apr 11, 2024
8-K
Current Report
Apr 04, 2024
ARS
ARS
Apr 04, 2024
DEF 14A
DEF 14A
Apr 04, 2024
DEFA14A
DEFA14A
Apr 03, 2024
4
Insider Trading
Apr 03, 2024
4
Insider Trading
Apr 03, 2024
4
Insider Trading
Apr 01, 2024
144
Notice of Insider Sale Intent
Apr 01, 2024
144
Notice of Insider Sale Intent
Mar 29, 2024
4
Insider Trading

Peers (Alternatives to Laboratory Corp of America Holdings)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
177.5B
23.9B
-6.01% -5.66%
37.43
7.43
-10.33% -33.23%
41.4B
3.7B
-7.85% 3.70%
48.95
11.3
8.72% 24.44%
41.2B
6.7B
-4.79% -0.38%
33.37
6.12
-2.81% -6.58%
14.2B
9.3B
-0.68% -9.91%
16.66
1.54
-6.38% -9.73%
13.0B
2.5B
16.81% 6.46%
-63.45
5.18
19.93% 67.26%
12.4B
4.1B
-7.63% 17.34%
26.1
3
3.86% -2.39%
12.2B
1.9B
-3.01% 103.01%
43.03
6.45
29.17% 15.26%
11.4B
1.1B
6.13% 81.38%
-26.22
10.53
31.99% 20.63%
MID-CAP
2.7B
929.2M
-20.76% -25.66%
1.7K
2.88
28.93% 111.61%
2.2B
563.9M
-3.74% -26.28%
-4.64
3.95
25.45% 26.76%
SMALL-CAP
440.6M
280.3M
-19.18% -10.04%
-2.32
1.57
-12.89% -148.37%
86.5M
31.2M
-2.40% -86.64%
-0.98
2.77
5.03% -1.81%
42.6M
9.2M
-5.99% -38.94%
-2.55
4.65
11.85% 44.12%
6.5M
9.0M
-20.83% -63.11%
-0.89
0.72
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Laboratory Corp of America Holdings News

Latest updates
TradingPedia28 hours ago
Marketscreener.com11 Apr 202411:00 am
Yahoo Finance09 Apr 202401:03 pm

Laboratory Corp of America Holdings Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-0.8%3,0333,0573,0343,6084,1822,8672,9236401,0714,0633,8414,16210,2209472,7692,8242,9532,9182,8822,8352,788
Cost Of Revenue-13.7%1,9042,2062,1922,8031,8291,9811,9812,6673282,6772,5762,5632,5852,3372,0082,0962,1332,1112,0572,0022,015
Gross Profit-10.8%7598518429757238869431,2337431,3861,2651,5991,9051,559761728821817825790772
  S&GA Expenses-7.8%485526506554434453432464282520459430518420396396414402415394397
Interest Expenses-3.0%49.0050.0050.0051.0049.0046.0042.0042.0043.0042.0078.0049.0048.0051.0053.0055.0064.0061.0059.0057.0058.00
Income Taxes-64.8%19.0055.0050.0065.00-35.6538.0092.0014875.0018018325230424365.0049.0066.0066.0079.0069.00384
Net Income-191.2%-16718318921376.00353359492553587467770938703232-317227-317190186158
Net Income Margin-38.8%0.03*0.06*0.06*0.08*0.09*0.17*0.17*0.17*0.15*0.17*0.18*----------
Free Cashflow141.7%41217126427.00502291442239548650390----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-1.0%16,72516,88617,71920,20020,15519,82620,40320,72820,38520,86720,41720,41720,07218,74017,84917,29818,04617,84817,74416,97116,185
  Current Assets-4.8%3,7653,9545,1214,6954,6254,3725,0315,2305,3316,0215,6945,6385,1254,0863,4132,8912,9812,9882,8492,8852,835
    Cash Equivalents-26.3%5377281,9313943214109781,2341,3812,0371,9631,8911,321667557324338361265349427
  Inventory2.9%475461488481471468436441401411421428423393342254245235220234237
  Net PPE3.2%2,9122,8212,7622,9442,7942,8852,8702,8082,8152,6922,7022,6972,7302,6092,6282,6102,6372,4632,5442,4581,740
  Goodwill-3.0%6,1436,3326,1828,1166,1248,2188,1148,1665,8917,9077,7457,7217,7527,6147,4237,3897,8657,8157,8447,3867,360
Liabilities-1.8%8,8358,9948,9149,83910,0409,7159,9829,98710,09110,32110,15110,37510,61410,48110,47710,26010,45910,59710,5809,8409,195
  Current Liabilities11.2%3,2252,9012,1832,8863,0792,5222,6432,6422,7832,8882,6673,3693,0793,0103,0342,4582,6562,5552,4962,5271,879
  Long Term Debt-8.4%4,0554,4285,0425,0525,0395,3345,3605,3835,4175,4175,4234,9215,4195,4175,4175,7905,7906,1016,1355,4965,991
    LT Debt, Non Current-8.4%4,0554,4285,0425,0525,0395,3345,3605,3835,4175,4175,4234,9215,4195,4175,4175,7905,7906,1016,1355,4965,991
Shareholder's Equity0.0%7,8757,8738,78510,34210,09710,09210,40110,72110,27310,60110,32210,0989,4378,2397,3537,0207,6447,0207,1447,1117,048
  Retained Earnings-2.2%7,8888,0708,83610,73010,58210,84510,89810,94810,45710,78710,41710,1729,4798,4647,761-7,9817,6777,4567,2657,157
  Additional Paid-In Capital717.0%38.005.0094.0048.00---29.00---67.0011081.0032.00-27.0048.0091.001,4011,451
Shares Outstanding-100.0%-85.0089.0010388.00104106112108112113114---------
Float---17,300---20,200---24,800---15,200------
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations110.4%5802763511216543745733566987674871,158775786371204570456254166486
  Share Based Compensation-21.5%27.0034.0027.0041.0024.0030.0026.0038.0021.0059.0024.0029.0027.0027.0040.0018.0024.0032.0027.0026.0021.00
Cashflow From Investing32.2%-330-487-253-99.70-273-563-242-573-254-407-90.40-132-128-285-123-106-152-239-750-140-146
Cashflow From Financing59.3%-446-1,0971,545-60.60-372-452-479-17.70-1,008-281-325-450-1.00-396-16.90-102-449-115415-103-802
  Dividend Payments-100.0%-64.0065.0064.00-65.0067.00--------------
  Buy Backs-100.9%-9.001,009--300400400-1,00030030069.00-34.2569.00-100275100200100400

LH Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Consolidated Statements of Operations [Abstract]   
Revenues$ 12,161.6$ 11,863.9$ 13,136.1
Cost of Revenue8,796.78,155.08,143.7
Gross profit3,364.93,708.94,992.4
Selling, general and administrative expenses2,021.41,763.11,690.3
Amortization of intangibles and other assets219.8193.6229.5
Goodwill and Intangible Asset Impairment349.0261.70.0
Restructuring and other special charges49.154.024.0
Operating income725.61,436.53,048.6
Interest expense(199.6)(179.8)(211.8)
Equity method income, net(1.4)5.426.5
Investment income28.87.58.8
Other, net15.5(32.2)15.5
Provision for income taxes188.5233.9690.0
Net earnings419.21,280.62,379.5
Less: Net earnings attributable to the noncontrolling interest(1.2)(1.5)(2.2)
Net earnings attributable to Laboratory Corporation of America Holdings$ 418.0$ 1,279.1$ 2,377.3
Income (Loss) from Continuing Operations, Per Basic Share$ 4.35$ 11.00$ 22.71
Earnings Per Share, Basic$ 4.80$ 14.05$ 24.60
Income (Loss) from Continuing Operations Before Income Taxes and Noncontrolling Interest$ 568.9$ 1,237.4$ 2,887.6
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest380.41,003.52,197.6
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest$ 38.8$ 277.1$ 181.9
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share$ 0.45$ 3.04$ 1.88
Income (Loss) from Continuing Operations, Per Diluted Share4.3310.9422.52
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share0.443.031.87
Earnings Per Share, Diluted$ 4.77$ 13.97$ 24.39

LH Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]  
Deferred Revenue, Revenue Recognized$ 78,900,000$ 99,700,000
Current assets:  
Cash and Cash Equivalents, at Carrying Value536,800,000320,600,000
Accounts receivable, net1,913,300,0001,785,500,000
Unbilled Contracts Receivable185,400,000211,800,000
Supplies inventory474,600,000470,600,000
Prepaid expenses and other655,300,000610,400,000
Disposal Group, Including Discontinued Operation, Assets, Current01,226,100,000
Total current assets3,765,400,0004,625,000,000
Property, plant and equipment, net2,911,800,0002,794,100,000
Goodwill, net6,142,500,0006,123,700,000
Intangible assets, net3,342,000,0003,123,600,000
Joint venture partnerships and equity method investments26,900,00065,700,000
Deferred Income Tax Assets, Net06,400,000
Other assets, net536,500,000378,400,000
Disposal Group, Including Discontinued Operation, Assets, Noncurrent03,038,200,000
Total assets16,725,100,00020,155,100,000
Current liabilities:  
Finance Lease, Liability, Current6,400,0006,000,000.0
Accounts payable827,500,000852,200,000
Accrued expenses and other804,000,000.0787,000,000.0
Deferred Revenue, Current421,700,000310,600,000
Operating Lease, Liability, Current165,800,000163,800,000
Short-term borrowings and current portion of long-term debt999,800,000301,300,000
Disposal Group, Including Discontinued Operation, Liabilities, Current0657,600,000
Total current liabilities3,225,200,0003,078,500,000
Long-term debt, less current portion4,054,700,0005,038,800,000
Total maturities, due beyond one year648,900,000652,900,000
Total maturities, due beyond one year78,600,00083,600,000
Deferred income taxes and other tax liabilities417,900,000543,400,000
Other liabilities409,300,000401,100,000
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent0241,300,000
Total liabilities8,834,600,00010,039,600,000
Commitments and contingent liabilities
Noncontrolling interest15,500,00018,900,000
Shareholders’ equity  
Common stock, 83.9 and 88.2 shares outstanding at December 31, 2023 and 2022, respectively7,700,0008,100,000
Additional paid-in capital38,400,0000
Retained earnings7,888,200,00010,581,700,000
Accumulated other comprehensive loss(59,300,000)(493,200,000)
Total shareholders’ equity7,875,000,00010,096,600,000
Total liabilities and shareholders’ equity$ 16,725,100,00020,155,100,000
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents 109,400,000
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net 436,500,000
Disposal Group, Including Discontinued Operation, Other Assets, Current 583,600,000
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current 96,600,000
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent 162,100,000
Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent 1,997,300,000
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent 823,300,000
Disposal Group, Including Discontinued Operation, Deferred Tax Assets 1,200,000
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent 54,300,000
Disposal Group, Including Discontinued Operation, Assets 4,264,300,000
Disposal Group, Including Discontinued Operation, Accounts Payable, Current 82,600,000
Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current 281,800,000
Disposal Group, Including Discontinued Operation, Deferred Revenue, Current 271,500,000
Disposal Group, Including Discontinued Operation, Short-term operating lease liabilities 21,700,000
Disposal Group, Including Discontinued Operation, Operating lease liabilities 26,800,000
Disposal Group, Including Discontinued Operation, Accrued Income Tax Payable, Noncurrent 192,800,000
Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent 21,700,000
Disposal Group, Including Discontinued Operation, Liabilities $ 898,900,000
LH
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
 CEO
 WEBSITElabcorp.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES60000

Laboratory Corp of America Holdings Frequently Asked Questions


What is the ticker symbol for Laboratory Corp of America Holdings? What does LH stand for in stocks?

LH is the stock ticker symbol of Laboratory Corp of America Holdings. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Laboratory Corp of America Holdings (LH)?

As of Fri Apr 12 2024, market cap of Laboratory Corp of America Holdings is 17.3 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LH stock?

You can check LH's fair value in chart for subscribers.

What is the fair value of LH stock?

You can check LH's fair value in chart for subscribers. The fair value of Laboratory Corp of America Holdings is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Laboratory Corp of America Holdings is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Laboratory Corp of America Holdings a good stock to buy?

The fair value guage provides a quick view whether LH is over valued or under valued. Whether Laboratory Corp of America Holdings is cheap or expensive depends on the assumptions which impact Laboratory Corp of America Holdings's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LH.

What is Laboratory Corp of America Holdings's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, LH's PE ratio (Price to Earnings) is 41.39 and Price to Sales (PS) ratio is 1.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Laboratory Corp of America Holdings's stock?

In the past 10 years, Laboratory Corp of America Holdings has provided 0.09 (multiply by 100 for percentage) rate of return.